OKYO Pharma Ltd
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- –
- Dividend yield
- –
About OKYO Pharma
Biological Products, (No Diagnostic Substances), SIC 2836
OKYO Pharma Limited is a biopharmaceutical company focused on developing treatments for ocular surface and anterior segment diseases. Its primary product candidate is urcosimod, formerly known as OK-101, which is in mid-stage development for neuropathic corneal pain and related conditions. It also advances OK-201, an early-stage therapeutic candidate. Because its pipeline remains in testing, the company generates no commercial product sales. Its prospective customers include patients suffering from ocular diseases and the medical professionals who treat them.
The company is incorporated in Guernsey and maintains its principal executive offices in St. Peter Port. It also maintains an executive presence in London, United Kingdom, and operates through a wholly owned subsidiary, OKYO Pharma Inc. Its developmental and regulatory activities involve the United States, the United Kingdom, and the European Union.
Summary of the business section of OKYO Pharma's latest annual report, written by StockData.
Company profile
Company
- Legal name
- OKYO Pharma Ltd
- Headquarters
- London, X0
- Address
- 55 Park Lane W1K 1NA
- Phone
- 44 (0) 207 495 2379
- Website
- okyopharma.com
- Employees
- 5, Mar 31, 2026
- Industry
- Biological Products, (No Diagnostic Substances)
- Auditor
- PKF Littlejohn LLP, London, England
Stock & identifiers
- Ticker
- OKYO
- Exchange
- Nasdaq
- IPO date
- May 18, 2022
- Shares outstanding
- 52M, Jul 15, 2026
- Filer category
- Non-accelerated filer<br>Emerging growth company
- SEC CIK
- 1849296
- CUSIP
- G6724L116
- ISIN
- USG6724L1165
- EIN
- 00-0000000
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Robert John Dempsey | CHIEF EXECUTIVE OFFICER, Director | 15,000 |
| Gary S. Jacob | CHIEF DEVELOPMENT OFFICER, Director | 112,420 |
| Rajkumar V. Patil | Chief Scientific Officer | 20,030 |
| Flavio Mantelli | CHIEF MEDICAL OFFICER | 20,000 |
| Keeren Rameshchandra Shah | Chief Financial Officer | 16,667 |
| Gabriele M. Cerrone | Director | 21,400,332 |
| John P. Brancaccio | Director | 35,201 |
| Bernard Denoyer | Director | – |
| Willy Jules Simon | Director | 15,383 |
Employees
Headcount reported in annual reports
“of March 31, 2026, we had 5 full time employees.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Jul 31, 2024 | Late filing | Notification of late filing |
| Jul 31, 2023 | Late filing | Notification of late filing |
| Aug 1, 2022 | Late filing | Notification of late filing |
| May 18, 2022 | IPO | Initial public offering priced (424B4 prospectus) |
| May 10, 2022 | Listing | Registration of securities on an exchange (Form 8-A) |